Genotyping was conducted by the Center for Inherited Disease Research (CIDR). Genotype data was obtained using the Illumina HumanOmni2.5 BeadChip, which measures ~2.4 million single nucleotide polymorphisms (SNPs). Individuals a with call rate <98% and with first degree relatives in the HRS were excluded from analysis. Principal components analysis was used to calculate genetic principal components (PCs) using SNPRelate [1] . The top two PCs and self-reported ethnic ancestry were used to select an analysis sample of unrelated European American (EA, N = 9991) and African American (AA, N = 2279) participants. SNPs a with call rate <98%, ethnicity-specific Hardy Weinberg equilibrium (HWE) p-value < 0.0001, and those in regions with chromosomal anomalies were also excluded. Imputation to the 1000 Genomes Project cosmopolitan reference panel phase 1, version 3 (released on March 2012) was performed using SHAPEIT2 [2] and IMPUTE2 [3] . Overall, ~23 million SNPs were imputed from the original 2,118,384 SNPs that were genotyped and passed quality control. Masking of genotyped SNPs to assess the accuracy of imputation was performed to estimate the median concordance between actual and imputed genotypes. The mean of empirical dosage correlation r 2 was 0.817 for rare variants (MAF < 0.05) and 0.953 for common variants (MAF ≥ 0.05), and additional quality control metrics indicate high quality imputation. For each ethnicity, genetic PCs were generated from common SNPs (MAF > 0.05) and were used as covariates to adjust for population stratification.
LGEWIS was used to test the association between gene/regions and BMI adjusting for age, sex and the top four genetic principal components. The tests were done separately for the European American and African American samples. P-values < 0.05 are in bold. "N markers" refers to the number of SNPs for each gene/region that was included in analysis. 
